Cited by 591Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesCutaneous Melanoma Detection and Management

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Antitumor Activity in Melanoma and Anti-Self Responses in a Phase I Trial With the Anti-Cytotoxic T Lymphocyte–Associated Antigen 4 Monoclonal Antibody CP-675,206

Ribas, Antoni, Camacho, Luis H., Lopez-Berestein, Gabriel, Pavlov, Dmitri, Bulanhagui, Cecile A., Millham, Robert, Comin-Anduix, Begoña, Reuben, James M., Seja, Elisabeth, Parker, Charla A., Sharma, Amarnath, Glaspy, John A., Gomez-Navarro, Jesus·2005·Journal of Clinical Oncology

DOI 10.1200/jco.2005.01.109

Open this paper in CoChat — free account

Abstract

Purpose: Cytotoxic T lymphocyte–associated antigen 4 (CTLA4) blockade with CP-675,206, a fully human anti-CTLA4 monoclonal antibody, may break peripheral immunologic tolerance leading to effective immune responses to cancer in humans. A phase I trial was conducted to test the safety of CP-675,206. Patients and Methods: Thirty-nine patients with solid malignancies (melanoma, n = 34; renal cell, n = 4; colon, n = 1) received an intravenous (IV) infusion of CP-675,206 at seven dose levels. The primary objective was to determine the maximum-tolerated dose and the recommended phase II dose. Results: Dose-limiting toxicities and autoimmune phenomena included diarrhea, dermatitis, vitiligo, panhypopituitarism and hyperthyroidism. Two patients experienced complete responses (maintained for 34+ and 25+ months), and there were two partial responses (26+ and 25+ months) among 29 patients with measurable melanoma. There have been no relapses thus far after objective response to therapy. Four other patients had stable disease at end of study evaluation (16, 7, 7, and 4 months). Additionally, five patients had extended periods without disease progression (36+, 35+, 26+, 24+, and 23+ months) after local treatment of progressive metastases. Longer systemic exposure to CP-675,206 achieved in higher dose cohorts predicted for a higher probability of response. Conclusion: CP-675,206 can be administered safely to humans as a single IV dose up to 15 mg/kg, resulting in breaking of peripheral immune tolerance to self-tissues and antitumor activity in melanoma.

Integrity signals

Registry

Crossref · 10.1200/jco.2005.01.109

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Cancer regression and autoimmunity induced by cytotoxic t lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
Middleton, M. R., Grob, J., Aaronson, N. K., Fierlbeck, G., Tilgen, W., Seiter, S., Gore, M. E., Aamdal, S., Cebon, J. S., Coates, A., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.158 · Cited by 1,270
CTLA-4–Ig regulates tryptophan catabolism in vivo
Grohmann, U., Orabona, C., Fallarino, F., Vacca, C., Calcinaro, F., Falorni, A., Candeloro, P., Belladonna, M. L., Bianchi, R., Fioretti, M. C., et al. (2002) · Nature Immunology · doi:10.1038/ni846 · Cited by 1,204
Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses
Sutmuller, R. P. M., van Duivenvoorde, L. M., van Elsas, A., Schumacher, T. N. M., Wildenberg, M. E., Allison, J. P., Toes, R. E. M., Offringa, R., & Melief, C. J. M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.823 · Cited by 1,008
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
Hodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830997100 · Cited by 1,006

Flagged first, then by citations

Show all 31 references

Sorted by citations

Items 301–400 of 591

Advances in tumour immunotherapy.
King, J., Waxman, J., & Stauss, H. J. (2008) · QJM : monthly journal of the Association of Physicians · doi:10.1093/qjmed/hcn050 · Cited by 26
Targeting Cytotoxic T-Lymphocyte Antigen 4 in Immunotherapies for Melanoma and Other Cancers
Page, D. B., Yuan, J. D., & Wolchok, J. D. (2010) · Immunotherapy · doi:10.2217/imt.10.21 · Cited by 23
Immune alterations in malignant melanoma and current immunotherapy concepts
Shimanovsky, A., Jethava, A., & Dasanu, C. A. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.827658 · Cited by 24
Clinical Activity, Toxicity, Biomarkers, and Future Development of CTLA-4 Checkpoint Antagonists
Callahan, M. K., & Wolchok, J. D. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.008 · Cited by 23
A twenty year perspective on melanoma therapy
Flaherty, K. T. (2023) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.13125 · Cited by 23
Melanoma immunotherapy dominates the field
Diamantopoulos, P. T., & Gogas, H. J. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.06.32 · Cited by 25
Inverse Relationship Between Alzheimer’s Disease and Cancer: How Immune Checkpoints Might Explain the Mechanisms Underlying Age-Related Diseases
Rogers, N. K., Romero, C., SanMartín, C. D., Ponce, D. P., Salech, F., López, M. N., Gleisner, M. A., Tempio, F., & Behrens, M. I. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190839 · Cited by 23
Single versus combined immunoregulatory approach using PD-1 and CTLA-4 modulators in controlling sepsis
Rudick, C. P., Cornell, D. L., & Agrawal, D. K. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1357469 · Cited by 22
Exposure–Response Analysis of Overall Survival for Tremelimumab in Unresectable Malignant Mesothelioma: The Confounding Effect of Disease Status
Baverel, P., Roskos, L. K., Tatipalli, M., Lee, N., Stockman, P. K., Taboada, M., Vicini, P., Horgan, K., & Narwal, R. (2019) · Clinical and Translational Science · doi:10.1111/cts.12633 · Cited by 22
The nexus of dynamic T cell states and immune checkpoint blockade therapy in the periphery and tumor microenvironment
Luo, H., Wang, W., Mai, J., Yin, R., Cai, X., & Li, Q. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1267918 · Cited by 22
Novel therapeutics for melanoma
Seetharamu, N., Ott, P. A., & Pavlick, A. C. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.40 · Cited by 22
Dendritic cell vaccination as a treatment modality for melanoma
Eubel, J., & Enk, A. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.139 · Cited by 22
New Molecular, Biological, and Immunological Agents Inducing Hypophysitis
Angelousi, A. G., Chatzellis, E., & Kaltsas, G. (2017) · Neuroendocrinology · doi:10.1159/000480086 · Cited by 22
Tremelimumab
June, I., BCG-resistant, P. I. A. O.-L. P. I. T. (. O. T. I. C. W. B. C.-G. (. I. P. W., safety, R. B. C. T. S. W. I. T., efficacy, & and immunogenicity of the therapy in approximately patients in the, U. S. (2010) · Drugs in R&D · doi:10.2165/11584530-000000000-00000 · Cited by 22
Anticorps anti-CTLA-4
Robert, C., & Mateus, C. (2011) · médecine/sciences · doi:10.1051/medsci/20112710013 · Cited by 22
Consolidation for Ovarian Cancer in Remission
Sabbatini, P. J., & Spriggs, D. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5138 · Cited by 22
Unleashing the Power of immune Checkpoints: A new strategy for enhancing Treg cells depletion to boost antitumor immunity
Li, G., Li, S., Jiang, Y., Chen, T., & An, Z. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113952 · Cited by 23
Durvalumab and tremelimumab combination therapy versus durvalumab or tremelimumab monotherapy for patients with solid tumors
Wang, B., Li, P., Fan, J., Lin, G., & Liu, Q. (2020) · Medicine · doi:10.1097/md.0000000000021273 · Cited by 21
The evaluation of immunotherapy and chemotherapy treatment on melanoma: a network meta-analysis
Ci-Ren, B.-S., Wang, X., & Long, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.13277 · Cited by 22
Immunotherapy in Renal Cell Carcinoma
Heine, A., Holderried, T. A. W., & Brossart, P. (2008) · Immunotherapy · doi:10.2217/1750743x.1.1.97 · Cited by 21
TAPCells, the Chilean dendritic cell vaccine against melanoma and prostate cancer
Salazar‐Onfray, F., Pereda, C., Reyes, D., & López, M. N. (2013) · Biological Research · doi:10.4067/s0716-97602013000400014 · Cited by 21
An Update on Malignant Melanoma Vaccine Research
Ralph, S. J. (2007) · American Journal of Clinical Dermatology · doi:10.2165/00128071-200708030-00001 · Cited by 20
Improving T cell therapy for cancer
Foster, A. E., & Rooney, C. M. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.3.215 · Cited by 22
Evolving Concepts: Immunity in Oncology from Targets to Treatments
Khan, H., Gucalp, R. A., & Shapira, I. (2015) · Journal of Oncology · doi:10.1155/2015/847383 · Cited by 20
Immune based therapy for melanoma
Ancuceanu, R., & Neagu, M. T. (2016) · The Indian Journal of Medical Research · doi:10.4103/0971-5916.180197 · Cited by 20
Endocrine dysfunction following immune checkpoint inhibitor therapy
Konda, B., Nabhan, F. A., & Shah, M. H. (2017) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000357 · Cited by 20
Antigen folding improves loading efficiency and antitumor efficacy of PC7A nanoparticle vaccine
Wilhelm, J., Quiñones-Pérez, M., Wang, J., Wang, X., Basava, V. S., & Gao, J. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.11.056 · Cited by 20
Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors
Hurkmans, D. P., Sassen, S. D. T., de Joode, K., Putter, L., Basak, E. A., Wijkhuijs, A. J. M., Joerger, M., Debets, R., Koch, B. C. P., van der Leest, C. H., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002344 · Cited by 20
Oncophage: step to the future for vaccine therapy in melanoma
di Pietro, A., Tosti, G., Ferrucci, P. F., & Testori, A. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712590802517970 · Cited by 21
Exploiting Regulatory T-cell Populations for the Immunotherapy of Cancer
van der Vliet, H. J., Koon, H. B., Atkins, M. B., Balk, S. P., & Exley, M. A. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31805ca058 · Cited by 20
Systemic Therapy for Cutaneous Melanoma
Treisman, J. S., & Garlie, N. K. (2009) · Clinics in Plastic Surgery · doi:10.1016/j.cps.2009.07.008 · Cited by 20
Gearing up T-cell immunotherapy in cervical cancer
Chauhan, S. R., & Bharadwaj, M. (2018) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2018.04.001 · Cited by 20
Immunotherapy for lung cancer: for whom the bell tolls?
Madureira, P., de Mello, R. A., de Vasconcelos, A., & Zhang, Y. (2015) · Tumor Biology · doi:10.1007/s13277-015-3285-6 · Cited by 19
Cytokine Working Group Study of Lymphodepleting Chemotherapy, Interleukin-2, and Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Metastatic Melanoma: Clinical Outcomes and Peripheral-Blood Cell Recovery
Gunturu, K. S., Meehan, K. R., MacKenzie, T. A., Crocenzi, T. S., McDermott, D. F., Usherwood, E. J., Margolin, K. A., Crosby, N. A., Atkins, M. B., Turk, M. J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.8153 · Cited by 20
Exploiting dendritic cells for active immunotherapy of cancer and chronic infections
O’Neill, D. W., & Bhardwaj, N. (2007) · Molecular Biotechnology · doi:10.1007/s12033-007-0020-6 · Cited by 19
Targeting metastatic melanoma
Poust, J. (2008) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080461 · Cited by 19
Exploiting Dendritic Cells for Active Immunotherapy of Cancer and Chronic Infection
O’Neill, D. W., & Bhardwaj, N. (2004) · Humana Press eBooks · doi:10.1385/1-59259-862-5:001 · Cited by 19
Natural Killer T Cells in Advanced Melanoma Patients Treated with Tremelimumab
Ibarrondo, F. J., Yang, O. O., Chodon, T., Avramis, E. V., Lee, Y., Sazegar, H., Jalil, J., Chmielowski, B., Koya, R. C., Schmid, I., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076829 · Cited by 18
Self-citation
Modulation of the immune response by heterogeneous monocytes and dendritic cells in lung cancer
Kwiecień, I., Rutkowska, E., Raniszewska, A., Rzepecki, P., & Domagala-Kulawik, J. J. (2021) · World Journal of Clinical Oncology · doi:10.5306/wjco.v12.i11.966 · Cited by 20
Metastatic melanoma in the older patient: immunologic insights and treatment outcomes
Hegde, U. P., Chakraborty, N. G., Mukherji, B., & Kels, J. M. G. (2011) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/erp.11.14 · Cited by 18
The European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeutics
Menis, J., Litière, S., Tryfonidis, K., & Golfinopoulos, V. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.06.19 · Cited by 20
Molecular targeted therapy for patients with melanoma: the promise of MAPK pathway inhibition and beyond
Sullivan, R. J., & Atkins, M. B. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.504709 · Cited by 18
Folate-conjugated immunoglobulin targets melanoma tumor cells for NK cell effector functions
Skinner, C. C., McMichael, E. L., Jaime‐Ramirez, A. C., Abrams, Z. B., Lee, R. J., & Carson, W. E. (2016) · Melanoma Research · doi:10.1097/cmr.0000000000000258 · Cited by 17
The clinical utility of cytotoxic T lymphocyte antigen 4 abrogation by human antibodies
Weber, J. S. (2006) · Melanoma Research · doi:10.1097/01.cmr.0000232292.06785.a3 · Cited by 18
Mechanistic Learning for Combinatorial Strategies With Immuno-oncology Drugs: Can Model-Informed Designs Help Investigators?
Ciccolini, J., Barbolosi, D., André, N., Barlési, F., & Benzekry, S. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00381 · Cited by 18
Novel Therapies in Melanoma
Scheier, B. Y., Amaria, R. N., Lewis, K. D., & Gonzalez, R. C. (2011) · Immunotherapy · doi:10.2217/imt.11.136 · Cited by 17
Frequency and clinical characteristics of hypophysitis and hypopituitarism in patients undergoing immunotherapy – A systematic review
Jacques, J. P., Valadares, L. P., Moura, A. C., de Oliveira, M. R. F., & Naves, L. A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1091185 · Cited by 17
Immunotherapy for lung cancer
Sathish, G., Monavarshini, L. K., Sundaram, K., Sendilvelan, S., & Gomathi, K. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155104 · Cited by 18
Monoclonal Antibodies in Dermatooncology—State of the Art and Future Perspectives
Bobrowicz, M., Zagożdżon, R., Domagała, J., Vasconcelos‐Berg, R., Guenova, E., & Winiarska, M. (2019) · Cancers · doi:10.3390/cancers11101420 · Cited by 17
Surveillance of the Eye and Vision in Clinical Trials of CP-675,206 for Metastatic Melanoma
Straatsma, B. R., Nusinowitz, S., Young, T. A., Gordon, L. K., Chun, M. W., Rosen, C., Seja, E., Economou, J. S., Glaspy, J. A., Bozon, V. A., et al. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.02.035 · Cited by 17
Self-citation
Novel anti-melanoma treatment: focus on immunotherapy
Hao, M.-Z., Zhou, W.-Y., Du, X.-L., Chen, K., Wang, G.-W., Yang, Y. P., & Yang, J. (2014) · 癌症：英文版 · doi:10.5732/cjc.014.10118 · Cited by 17
HSPPC-96 vaccine in metastatic melanoma patients: from the state of the art to a possible future
Tosti, G., di Pietro, A., Ferrucci, P. F., & Testori, A. (2009) · Expert Review of Vaccines · doi:10.1586/erv.09.108 · Cited by 17
Current Trends in Glioblastoma Multiforme Treatment: Radiation Therapy and Immune Checkpoint Inhibitors
Nicholas, S. E., Mathios, D., Ruzevick, J., Jackson, C. M., Yang, I., & Lim, M. K. (2013) · Brain Tumor Research and Treatment · doi:10.14791/btrt.2013.1.1.2 · Cited by 16
Immunotherapy against cancer: A comprehensive review
Minda, A. G., Awel, F. S., Seifudin, K. A., & Mamo, G. (2016) · Journal of Cancer Research and Experimental Oncology · doi:10.5897/jcreo2015.0124 · Cited by 16
Immunotherapy of advanced or metastatic melanoma.
Cebon, J. S., Gedye, C. A., John, T., & Davis, I. D. (2007) · PubMed · Cited by 16
A Review of Advanced Cutaneous Melanoma Therapies and Their Mechanisms, from Immunotherapies to Lysine Histone Methyl Transferase Inhibitors
Filho, R. S. D. O., de Oliveira, D. A., Nisimoto, M. Y. S. M., & Marti, L. C. (2023) · Cancers · doi:10.3390/cancers15245751 · Cited by 15
Melanoma
Blesa, J. M. G., Pulido, E. G., Candel, V. A., & Provencio, M. (2010) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e3181d6b427 · Cited by 15
Melanoma Immunotherapy
Sivendran, S., Glodny, B., Pan, M. M., Mérad, M., & Saenger, Y. M. (2010) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20215 · Cited by 15
Immune-Checkpoints : les nouvelles immunothérapies anticancéreuses
Ileana, E. E., Champiat, S., & Soria, J. (2013) · Bulletin du Cancer · doi:10.1684/bdc.2013.1771 · Cited by 16
Head and neck cancer immunotherapy: Clinical evaluation
Leibowitz, M. S., Nayak, J. V., & Ferris, R. L. (2008) · Current Oncology Reports · doi:10.1007/s11912-008-0025-8 · Cited by 15
Molecular-targeted therapy in malignant melanoma
Sullivan, R. J., & Atkins, M. B. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.20 · Cited by 15
Dendritic cell transfer for cancer immunotherapy
Zhao, L., Zhang, S., Kepp, O., Kroemer, G., & Liu, P. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.03.003 · Cited by 14
Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis
Wang, B., Xiao, B., Li, P., Kuang, B., Chen, W., Li, P., Lin, G., Liu, Q., & You, S. (2020) · Journal of Oncology · doi:10.1155/2020/2368164 · Cited by 14
Trends in Cancer Immunotherapy
Murphy, J. F. (2010) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s4795 · Cited by 15
Transient Hypophysitis after Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA4) Blockade
Shaw, S. A., Camacho, L. H., McCutcheon, I. E., & Waguespack, S. G. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2484 · Cited by 14
Self-citation
Harnessing Immune Checkpoints for Cancer Therapy
Vinay, D. S., & Kwon, B. S. (2018) · Immunotherapy · doi:10.2217/imt-2017-0168 · Cited by 14
Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small Cell Lung Cancer: The Phase II BALTIC Study
Reinmuth, N., Juan, Ó., Kowalski, D. M., Bryl, M., Kryzhanivska, A., Vicente, D., Horváth, Z., Gálffy, G., Csánky, E., Székely, Z. P., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0013 · Cited by 12
The Consequence of Immune Suppressive Cells in the Use of Therapeutic Cancer Vaccines and Their Importance in Immune Monitoring
Vergati, M., Schlom, J., & Tsang, K. Y. (2011) · BioMed Research International · doi:10.1155/2011/182413 · Cited by 11
Inhibitors of B7–CD28 Costimulation in Urologic Malignancies
Thompson, R. H., Kwon, E. D., & Allison, J. P. (2008) · Immunotherapy · doi:10.2217/1750743x.1.1.129 · Cited by 12
Destruction of solid tumors by immune cells
López, Á. G., Seoane, J. M., & Sanjuán, M. A. F. (2016) · Communications in Nonlinear Science and Numerical Simulation · doi:10.1016/j.cnsns.2016.08.020 · Cited by 12
Costimulation in Lymphomas and Cancers
Mir, M. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-802585-7.00005-4 · Cited by 12
Pharmacogenomics in dermatology: from susceptibility genes to personalized therapy
Pincelli, C., Pignatti, M., & Borroni, R. G. (2009) · Experimental Dermatology · doi:10.1111/j.1600-0625.2009.00852.x · Cited by 12
B7-H4 as an independent prognostic indicator of cancer patients: a meta-analysis
Meng, Z., Wang, F., Zhang, Y., Li, S., & Wu, H. (2017) · Oncotarget · doi:10.18632/oncotarget.18566 · Cited by 12
More Support for the Judicious Use of High-Dose Interleukin-2 in Patients With Advanced Melanoma
McDermott, D. F., & Atkins, M. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.9552 · Cited by 12
Toxicité dermatologique des nouvelles thérapies ciblées anticancéreuses utilisées en oncodermatologie
Sibaud, V., Delord, J., Chevreau, C., Gangloff, D., & Garrido, I. (2012) · Annales de Chirurgie Plastique Esthétique · doi:10.1016/j.anplas.2012.02.002 · Cited by 11
Combined induction with anti-PD-1 and anti-CTLA-4 antibodies provides synergistic antitumor effects in DC-CIK cells in renal carcinoma cell lines.
Yuan, Z., Yang, H., & Wei, Y. (2019) · Europe PMC (PubMed Central) · Cited by 11
Antinuclear antibody (ANA) status predicts immune-related adverse events in liver cancer patients undergoing anti-PD-1 therapy
Hsu, S.-J., Chao, Y., Lin, X., Liu, H., Zhang, Y., Hong, W.-F., Chen, M., Xu, X., Zhang, L., Ren, Z., et al. (2023) · Clinical & Experimental Immunology · doi:10.1093/cei/uxad036 · Cited by 12
Anti-CTLA-4 (CD 152) monoclonal antibody-induced autoimmune interstitial nephritis
Jolly, E. C., Clatworthy, M. R., Lawrence, C., Nathan, P., & Farrington, K. (2009) · Clinical Kidney Journal · doi:10.1093/ndtplus/sfp048 · Cited by 11
Can graft-versus-leukemia reactivity be dissociated from graft-versus-host disease?
Sprangers, B. (2007) · Frontiers in bioscience · doi:10.2741/2411 · Cited by 11
Tumor Stabilization Induced by T-Cell Recruitment Fluctuations
Bashkirtseva, I., Ryashko, L., López, Á. G., Seoane, J. M., & Sanjuán, M. A. F. (2020) · International Journal of Bifurcation and Chaos · doi:10.1142/s0218127420501795 · Cited by 10
Immunotherapeutic Strategies: The Melanoma Example
Jorritsma, A., Schumacher, T. N., & Haanen, J. B. A. G. (2009) · Immunotherapy · doi:10.2217/imt.09.20 · Cited by 10
Does the Immunocompetent Status of Cancer Patients Have an Impact on Therapeutic DC Vaccination Strategies?
Lluesma, S. M., Graciotti, M., Chiang, C. L.-L., & Kandalaft, L. E. (2018) · Vaccines · doi:10.3390/vaccines6040079 · Cited by 11
Endocrinopatías autoinmunitarias inducidas por anticuerpos inmunomoduladores en el tratamiento del cáncer
Iglesias, P., Soria, A., & Díez, J. J. (2015) · Medicina Clínica · doi:10.1016/j.medcli.2015.02.010 · Cited by 10
Immunotherapy for melanoma
Lacy, K. E., Karagiannis, S. N., & Nestle, F. O. (2012) · Expert Review of Dermatology · doi:10.1586/edm.11.80 · Cited by 10
Immunologic targeting of the cancer stem cell
Wu, C. J. (2008) · StemBook · doi:10.3824/stembook.1.21.1 · Cited by 10
Population pharmacokinetic modelling of tremelimumab in patients with advanced solid tumours and the impact of disease status on time‐varying clearance
Hwang, M., Chia, Y. L., Zheng, Y., Chen, C. C., He, Z., Song, X., Zhou, D., Goldberg, S. B., Siu, L. L., Planchard, D., et al. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15622 · Cited by 9
Novel avenues in immunotherapies for colorectal cancer
Pardieck, I. N., Jawahier, P. A., Swets, M., van de Velde, C. J. �., & Kuppen, P. J. K. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2016.1122522 · Cited by 9
Anti-regulatory T cell vaccines in immunotherapy: focusing on FoxP3 as target
Mousavi-Niri, N., Naseroleslami, M., & Hadjati, J. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1545625 · Cited by 9
The Promising Role of Monoclonal Antibodies for Gastric Cancer Treatment
Afshari, F., Soleymanjahi, S., Keshavarz‐Fathi, M., Roviello, G., & Rezaei, N. (2019) · Immunotherapy · doi:10.2217/imt-2018-0093 · Cited by 9
Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease.
Yu, S. S., Dorff, T. B., Ballas, L., Sadeghi, S., Skinner, E. C., & Quinn, D. I. (2017) · PubMed · Cited by 9
Molecularly targeted therapy and immunotherapy for hormone receptor‑positive/human epidermal growth factor receptor 2‑negative advanced breast cancer (Review)
Song, Y., He, L., Wang, Y., Wu, Q., & Huang, W. (2020) · Oncology Reports · doi:10.3892/or.2020.7589 · Cited by 9
Monoclonal antibody therapy
Dillman, R. O. (2009) · Springer eBooks · doi:10.1007/978-90-481-2289-9_10 · Cited by 9
Immunotherapy of melanoma
Hersey, P. (2010) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/j.1743-7563.2010.01269.x · Cited by 9
Immunotherapy of Melanoma: An Update
Homsi, J., Grimm, J. C., & Hwu, P. (2010) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2010.09.004 · Cited by 9
The immunological era in melanoma treatment: new challenges for heat shock protein-based vaccine in the advanced disease
di Pietro, A., Tosti, G., Ferrucci, P. F., & Testori, A. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.605353 · Cited by 9
Progress and challenges in the vaccine-based treatment of head and neck cancers
Venuti, A. (2009) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-28-69 · Cited by 9
Gemcitabine treatment enhanced the anti-tumor effect of cytokine induced killer cells by depletion of CD4+CD25bri regulatory T cells
Zhao, P., Zhu, D. Y., Zhang, Z., Han, B., Gao, D., Wei, X., Xie, X., Li, C., Sun, W., Wang, Q., et al. (2016) · Immunology Letters · doi:10.1016/j.imlet.2016.11.009 · Cited by 9
Predicting Method for the Human Plasma Concentration–Time Profile of a Monoclonal Antibody from the Half-life of Non-human Primates
Nakamura, G., Ozeki, K., Nagayasu, M., Nambu, T., Nemoto, T., & Hosoya, K. (2020) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b19-01042 · Cited by 10
Dendritic Cell-Based Cancer Vaccines
Westdorp, H., Bol, K. F., Coskuntürk, M., Schreibelt, G., de Vries, I. J. M., & Figdor, C. G. (2014) · Springer eBooks · doi:10.1007/978-3-319-05104-8_8 · Cited by 9
Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data
Yin, J., Paolettí, X., Sargent, D. J., & Mandrekar, S. J. (2017) · Clinical Trials · doi:10.1177/1740774517723829 · Cited by 9

Authors: Ribas, A., Camacho, L. H., Lopez-Berestein, G., Pavlov, D., Bulanhagui, C. A., Millham, R., Comin-Anduix, B., Reuben, J. M., Seja, E., Parker, C. A., Sharma, A., Glaspy, J. A., & Gomez-Navarro, J.
Affiliations: The University of Texas MD Anderson Cancer Center (US)
From the Departments of Medicine, Division of Hematology/Oncology; Surgery, Division of Surgical Oncology and UCLA Jonsson Comprehensive Cancer Center, University of California at Los Angeles, Los Angeles, CA; Departments of Experimental Therapeutics, Melanoma Medical Oncology and Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX; and Pfizer Global Research and Development, Groton-New London, CT
ORCID: Ribas, Antoni
Camacho, Luis H.
Reuben, James M.
Sharma, Amarnath
Glaspy, John A.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2005-12-10
Volume: 23
Issue: 35
Pages: 8968-8977
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2005.01.109
OpenAlex: W2163184777
Cited by: 591
References: 31
Citations by year: 2026: 4 · 2025: 1 · 2024: 11 · 2023: 18 · 2022: 19 · 2021: 21 · 2020: 24 · 2019: 29 · 2018: 24 · 2017: 32 · 2016: 33 · 2015: 29 · 2014: 25 · 2013: 38 · 2012: 27
FWCI: 22.08
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: American Society of Clinical Oncology
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
Keywords: CTLA-4 blockade, melanoma, antitumor immunity, peripheral tolerance, autoimmune adverse events, maximum tolerated dose, dose-limiting toxicity, complete response, renal cell carcinoma, colon cancer, immunotherapy safety
MeSH terms: Adult, Aged, Antibodies, Monoclonal, Antibodies, Neoplasm, Antigens, Differentiation, Antigens, Neoplasm, Autoimmune Diseases, Colonic Neoplasms, Female, Humans, Immune Tolerance, Immunotherapy, Infusions, Intravenous, Kidney Neoplasms, Male, Melanoma, Middle Aged, Neoplasm Proteins, Neoplasms, Regression Analysis, Antigens, CD, T-Lymphocyte Subsets, Treatment Outcome, Antibodies, Blocking, Cancer Vaccines, MART-1 Antigen, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Antitumor Activity in Melanoma and Anti-Self Responses in a Phase I Trial With the Anti-Cytotoxic T Lymphocyte–Associated Antigen 4 Monoclonal Antibody CP-675,206

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks